DOP2018000174A - Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 - Google Patents

Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1

Info

Publication number
DOP2018000174A
DOP2018000174A DO2018000174A DO2018000174A DOP2018000174A DO P2018000174 A DOP2018000174 A DO P2018000174A DO 2018000174 A DO2018000174 A DO 2018000174A DO 2018000174 A DO2018000174 A DO 2018000174A DO P2018000174 A DOP2018000174 A DO P2018000174A
Authority
DO
Dominican Republic
Prior art keywords
hiv
inhibitors
compounds
triterpenoids
modified
Prior art date
Application number
DO2018000174A
Other languages
English (en)
Inventor
Sit Sing-Yuen
Chen Yan
Swidorski Jacob
Lee Venables Brian
Sin Ny
A Meanwell Nicholas
A Hartz Richard
Chen Jie
B Dicker Ira
Nowicka-Sans Beata (Fallecida)
Regueiro-Ren Alicia
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of DOP2018000174A publication Critical patent/DOP2018000174A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/52Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se exponen compuestos que tienen propiedades farmacológicas y que afectan a la bioactividad, sus composiciones farmacéuticas y procedimientos de uso. En particular, se proporcionan derivados de ácido betulínico que poseen actividad antivírica única como inhibidores de la maduración del VIH, tal como se representa mediante los compuestos de fórmula I: Estos compuestos son útiles para el tratamiento del VIH y del sida.
DO2018000174A 2016-02-04 2018-07-30 Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 DOP2018000174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (1)

Publication Number Publication Date
DOP2018000174A true DOP2018000174A (es) 2018-10-31

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000174A DOP2018000174A (es) 2016-02-04 2018-07-30 Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1

Country Status (38)

Country Link
US (4) US10421774B2 (es)
EP (2) EP3831839B1 (es)
JP (1) JP6735837B2 (es)
KR (1) KR20180105229A (es)
CN (1) CN109153700B (es)
AR (1) AR107512A1 (es)
AU (1) AU2017215529B2 (es)
BR (1) BR112018015629B1 (es)
CA (1) CA3013417C (es)
CL (1) CL2018002084A1 (es)
CO (1) CO2018008157A2 (es)
CR (1) CR20180387A (es)
CY (1) CY1124353T1 (es)
DK (1) DK3411381T3 (es)
DO (1) DOP2018000174A (es)
EA (1) EA036211B1 (es)
ES (2) ES2862325T3 (es)
HK (1) HK1256866A1 (es)
HR (1) HRP20210502T1 (es)
HU (1) HUE054337T2 (es)
IL (1) IL260741B (es)
JO (1) JOP20170029B1 (es)
LT (1) LT3411381T (es)
MA (2) MA53358A (es)
MD (1) MD3411381T2 (es)
MX (1) MX2018009514A (es)
PE (1) PE20181355A1 (es)
PL (1) PL3411381T3 (es)
PT (1) PT3411381T (es)
RS (1) RS61746B1 (es)
RU (1) RU2716502C2 (es)
SG (1) SG11201806388XA (es)
SI (1) SI3411381T1 (es)
TW (1) TWI719126B (es)
UA (1) UA123867C2 (es)
UY (1) UY37109A (es)
WO (1) WO2017134596A1 (es)
ZA (1) ZA201805044B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
TW202135815A (zh) 2019-12-09 2021-10-01 美商 Viiv 醫療保健公司 醫藥組合物
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
RS54352B1 (en) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
AU2012352129B2 (en) * 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
CA2944778C (en) 2014-04-11 2022-06-14 ViiV Healthcare UK (No.4) Limited Triterpenoids with hiv maturation inhibitory activity
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
ES2907373T3 (es) 2016-02-04 2022-04-25 Takeda Pharmaceuticals Co Compuesto de piperidina sustituida y uso de la misma

Also Published As

Publication number Publication date
TW201739757A (zh) 2017-11-16
UY37109A (es) 2017-09-29
WO2017134596A1 (en) 2017-08-10
EP3411381B1 (en) 2021-01-20
EA201891649A1 (ru) 2019-02-28
EP3831839A2 (en) 2021-06-09
US20210323997A1 (en) 2021-10-21
RU2716502C2 (ru) 2020-03-12
EA036211B1 (ru) 2020-10-14
CY1124353T1 (el) 2022-07-22
RU2018130181A (ru) 2020-03-05
AU2017215529A8 (en) 2018-08-30
CA3013417C (en) 2024-01-02
CR20180387A (es) 2018-09-20
BR112018015629B1 (pt) 2023-10-24
SG11201806388XA (en) 2018-08-30
CN109153700B (zh) 2021-03-09
US20190359647A1 (en) 2019-11-28
IL260741B (en) 2020-04-30
CL2018002084A1 (es) 2018-09-21
EP3831839A3 (en) 2021-07-21
MA43960B1 (fr) 2021-02-26
TWI719126B (zh) 2021-02-21
AU2017215529A1 (en) 2018-08-23
AR107512A1 (es) 2018-05-09
CO2018008157A2 (es) 2018-08-21
MA43960A (fr) 2018-12-12
PE20181355A1 (es) 2018-08-22
US20190031709A1 (en) 2019-01-31
PT3411381T (pt) 2021-03-18
MA53358A (fr) 2021-07-21
US10421774B2 (en) 2019-09-24
MX2018009514A (es) 2018-09-05
ES2862325T3 (es) 2021-10-07
AU2017215529B2 (en) 2019-01-31
JOP20170029B1 (ar) 2021-08-17
RS61746B1 (sr) 2021-05-31
BR112018015629A2 (pt) 2018-12-26
HRP20210502T1 (hr) 2021-05-14
HK1256866A1 (zh) 2019-10-04
ZA201805044B (en) 2020-08-26
US20230295220A1 (en) 2023-09-21
HUE054337T2 (hu) 2021-08-30
PL3411381T3 (pl) 2021-09-13
ES2957767T3 (es) 2024-01-25
JP2019504104A (ja) 2019-02-14
CA3013417A1 (en) 2017-08-10
LT3411381T (lt) 2021-04-26
US11084845B2 (en) 2021-08-10
EP3831839B1 (en) 2023-07-26
JP6735837B2 (ja) 2020-08-05
MD3411381T2 (ro) 2021-07-31
RU2018130181A3 (es) 2020-03-05
DK3411381T3 (da) 2021-04-06
EP3411381A1 (en) 2018-12-12
SI3411381T1 (sl) 2021-04-30
KR20180105229A (ko) 2018-09-27
UA123867C2 (uk) 2021-06-16
CN109153700A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
CO6751275A2 (es) Triterpenoides c-17 y c-3 modificados con la actividad inhibidora de la maduración del virus de inmunodeficiencia humana
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2018008157A2 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
UY35213A (es) Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
DOP2016000277A (es) Triterpenoides con actividad inhibidora de la maduración del vih
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
CO2018010689A2 (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2017008765A2 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih
CL2017000428A1 (es) Derivados de imidazo[1,2-a]piridina para su uso como inhibidores para la replica del virus de la inmunodeficiencia humana
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
BR112017009853A2 (pt) composto, composição, uso de uma quantidade melhoradora de hiv de um composto
BR112017009852A2 (pt) composto, composição, e, usos de um composto